| Date | Title | Description | |
|---|---|---|---|
| 23 Feb 2022 | On business and financial situation | The Company releases the press release related to the full year 2021 financial results | Download |
| 23 Feb 2022 | On business and financial situation | The Company releases the full year 2021 financial results presentation | Download |
| 23 Feb 2022 | About corporate governance | The Company informs about the agreements adopted by the Board of Directors | Download |
| 22 Feb 2022 | On buy-back programmes | ROVI reports the end of the share buy-back programme, effective as of 3 November 2021, and the launching of a new share buy-back programme, effective as of 23 February 2022. | Download |
| 16 Feb 2022 | On business and financial situation | Moderna and ROVI announced that they expand their long-term collaboration for the manufacture of mRNA medicines over the next ten years | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 22 Sep 2023 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 15 September and 21 September 2023 | Download |
| 15 Sep 2023 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 8 September and 14 September 2023 | Download |
| 08 Sep 2023 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 1 September and 7 September 2023 | Download |
| 01 Sep 2023 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 25 August and 31 August 2023 | Download |
| 25 Aug 2023 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 18 August and 24 August 2023 | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 04 Apr 2019 | Liquidity contracts and specialists | Liquidity contract: transactions conducted in the first quarter of 2019 | Download |
| 19 Mar 2019 | R&D: new licenses, patents and registered trademarks | ROVI Announces Positive Topline Results from Phase 3 study of Doria® in Patients with Schizophrenia | Download |
| 26 Feb 2019 | Informe Anual de Remuneraciones de los Consejeros | ROVI releases the 2018 annual report regarding remuneration of the members of the Board of Directors | Download |
| 26 Feb 2019 | Informe Anual de Gobierno Corporativo | ROVI releases the 2018 Annual Corporate Governance Report | Download |
| 26 Feb 2019 | Otros sobre gobierno corporativo | The Company informs about the agreements adopted by the Board of Directors | Download |